Market Overview

Surmodics IVD Launches Breakthrough MatrixGuard™ Diluent

Share:

Surmodics, Inc. (NASDAQ:SRDX), the global leader in chemical components
for in vitro diagnostic (IVD) tests and microarrays, has
announced the launch and immediate availability of MatrixGuard™ Diluent. MatrixGuard
Diluent
provides assay developers unsurpassed blocking whereby
matrix interferences are effectively blocked while the intended assay
signal is maintained.

Unlike other diluents that either are marginally effective at blocking
matrix interferences or alternatively block out true assay signal, MatrixGuard
Diluent
achieves the goal of maximum blockade of matrix
interferences while simultaneously allowing the intended signal to be
maintained. MatrixGuard Diluent significantly reduces the risk of
false positives and has excellent three-year stability. Along with all
Surmodics reagents, MatrixGuard Diluent is manufactured in
Surmodics' ISO 13485 and 9001 certified facility to ensure quality and
lot-to-lot consistency.

With the launch of MatrixGuard Diluent, we continue our
commitment to be a premier provider of assay components to improve
performance and manufacturability of immunoassays," said Joe Stich, Vice
President and General Manager of Surmodics IVD, the company's In Vitro
Diagnostic business. "The Surmodics IVD team has truly developed a new
gold standard diluent for assay developers that consistently balances
outstanding blocking activity of matrix interferences while maintaining
assay signal across multiple assay formats."

Surmodics IVD products immediately improve assay performance and
manufacturability of assays by lowering backgrounds, increasing signal
generation and providing longer shelf lives for immunoassay production.
The addition of MatrixGuard Diluent augments the company's
leading portfolio of products, including:

  • The Immunoassay Stabilizer family preserves the conformation and
    activity of dried proteins coated on a wide range of surfaces, keeping
    antibodies and antigens at peak performance for long durations. At the
    same time, the blocking mechanisms in these reagents reduce
    non-specific binding of interfering proteins to maximize assay
    sensitivity.
  • The StabilZyme® family provides unparalleled long-term
    stability of protein conjugates at working strength concentrations.
    Surmodics formulations for HRP conjugates, AP conjugates and general
    protein applications ensure that assay developers have a complete set
    of tools to address the labile nature of each protein of interest.
  • BioFX® TMB substrate family outperforms competitors for low
    background, stability and sensitivity with a variety of kinetic rate
    substrates. The one-component formulations provide optimal signal
    generation and longer shelf lives.

About Surmodics, Inc.

Surmodics is the global leader in surface modification technologies for
intravascular medical devices and a leading provider of chemical
components for in vitro diagnostic (IVD) immunoassay tests and
microarrays. Surmodics is pursuing highly differentiated whole-product
solutions that are designed to address unmet clinical needs for its
medical device customers and engineered to the most demanding
requirements. This key growth strategy leverages the combination of the
Company's expertise in proprietary surface technologies, along with
enhanced device design, development and manufacturing capabilities. The
Company mission remains to improve the detection and treatment of
disease.

Surmodics is headquartered in Eden Prairie, Minnesota. For more
information, visit our IVD website at www.surmodics.com/ivd.
The content of Surmodics' website is not part of this press release or
part of any filings that the company makes with the SEC.

View Comments and Join the Discussion!